Background: Greek mountain tea (GMT), Herba Sideritis (Sideritis scardica Griseb.), is traditionally used to treat the common cold and mild gastrointestinal disorders. Sideritis spp. has been characterized as a genus with more than 150 perennial species widely distributed in the Mediterranean and the Canary and Madeira Islands. GMT was adopted in 2015 in the European Union as a traditional herbal medicine. Recent studies suggest its potential efficacy for reducing the risk of age-related cognitive decline and neurodegenerative diseases, which could be associated with the common mechanisms of action.
Aims and Hypothesis: The aims of this monograph were: (i) to
systematically update new evidence of the quality, efficacy, and safety of GMT
preparations and validate their potential health benefits, and (ii) to elaborate
a rationale for a mode of polyvalent pharmacological action, which is likely
associated with a regulation of the neuroendocrine-immune complex (stress
system).
Methods: Literature screening using the Pubmed database and
original publications were assessed according to WHO criteria for monographs of
herbal medicines.
Results: Sideritis
scardica extracts and its ingredient phenylethyl-phenylpropanoid glycoside
acteoside (AC, syn. verbascoside) exhibited cognitive improvement,
stress-protective, neuroprotective, neurogenesis, anxiolytic, anti-aging,
anti-inflammatory, antimicrobial, gastroprotective, glycemic, anti-obesity,
antioxidant, and anti-tumor activity. According to the findings, the
combination of Sideritis scardica with vitamin B may be relevant for persons
solving cognitive tasks under conflict and/or noise (e.g., open-plan offices or
car-driving) and support that the tested product alleviates stress-induced
impairment of executive functioning (working memory, cognitive flexibility,
controlled behavioral inhibition). The recent findings supported by preclinical
and clinical data suggest using Herba Sideritis extracts to improve cognitive
functions and mental disorders in aging.
Conclusion: This monograph provides systematic information
on the safety, efficacy, and quality of Herba Sideritis, paving the way for its
potential use in reducing the risk of age-related cognitive decline and
neurodegenerative disorders. It includes details of botanical descriptions,
chemical constituents, dosage recommendations, adverse effects, and
interactions for health professionals, researchers, and policymakers aiding in
evidence-based practices and ensuring the safe use of medicinal products.
Further preclinical and clinical research is crucial to fully validate GMT's
health benefits and unravel the mechanisms underlying its adaptogenic effects.
Author (s) Details
Alexander Panossian
Phytomed AB, Sjostadsvagen 6A, Lgh 1004, 59344 Vastervik, Sweden.
Terrence Lemerond
EuroPharma USA Inc., Green Bay, WI 54311, USA.
Please see the book here:- https://doi.org/10.9734/bpi/mono/978-93-48119-26-1
No comments:
Post a Comment